Until recently, ophthalmology wasn't particularly hot. As a niche area requiring specialist delivery expertise, given the unique environment of the eye, this wasn't where Big Pharma was going to find blockbusters.
Pfizer Inc. 's high profile entry into the field signalled change. First, it got the anti-glaucoma drug latanoprost (Xalatan)...